Roche Receives FDA CLIA Waiver for Flu A/B Test for use on its cobas® Liat® PCR System.
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted CLIA (Clinical Laboratory Improvement Amendments) Waiver for the cobas® Influenza A/B test for use on the cobas® Liat® System.
Read more
Roche Receives FDA CLIA Waiver for the cobas® Liat® PCR System and cobas® Strep A Assay
cobas® Strep A, the first molecular PCR test to deliver laboratory-quality results in ~15 minutes, now available for use in physician offices and pharmacies
Read more
Roche Launches PCR Molecular Diagnostic System for Point-of-Care Environment
The cobas® Liat® System is the only FDA cleared molecular diagnostic platform to offer real- time PCR results in 20 minutes or less
Read more
Roche Receives FDA Clearance for Strep A Test on cobas® Liat® System (English)
The cobas® Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection
Read more Roche Receives FDA Clearance for Strep A Test on cobas® Liat® System (French)
Le test cobas® Strep A est le premier test moléculaire réalisé au point de soins qui offre un résultat en 15 minutes pour cette infection courante
Read more Roche Receives FDA Clearance for Strep A Test on cobas® Liat® System (Spanish)
La prueba cobas® Strep A es la primera prueba molecular de análisis inmediato que proporciona un resultado en 15 minutos para esta infección tan común
Read more